Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

ABSTRACT: Over the past four decades, the number of people with Type 1 Diabetes (T1D) has increased by 4% per year, making it an important public health challenge. Currently, no curative therapy exists for T1D and the only available treatment is insulin replacement. HLA-DQ8 has been shown to present antigenic islet peptides driving the activation of CD4⁺ T-cells in T1D patients. Specifically, the insulin peptide InsB:9-23 activates self-reactive CD4⁺ T-cells, causing pancreatic beta cell destruction. The aim of the current study was to identify retro-inverso-d-amino acid based peptides (RI-D-peptides) that can suppress T-cell activation by blocking the presentation of InsB:9-23 peptide within HLA-DQ8 pocket. We identified a RI-D-peptide (RI-EXT) that inhibited InsB:9-23 binding

SUBMITTER: Lombardi A 

PROVIDER: S-EPMC7683378 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature